8-K/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported)       January 18, 2008

INSPIRE PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

     Delaware                                    000-31135                            04-3209022
(State or Other Jurisdiction(Commission        (IRS Employer
of Incorporation)                            File Number) Identification No.)

4222 Emperor Boulevard, Suite 200, Durham, North Carolina            27703-8466
(Address of Principal Executive Offices)(Zip Code)

Registrant's telephone number, including area code          (919) 941-9777

____________________________________________
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01      Regulation FD Disclosure.

On January 18, 2008, Inspire issued a press release, attached to and made part of this report, announcing revenue and expense guidance for the full year 2008.

Item 9.01Financial Statements and Exhibits.

Exhibits

No.               Description

99.1              Press Release dated January 18, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                                                         Inspire Pharmaceuticals, Inc.

                                                                         By: /s/ Thomas R. Staab, II                        
                                                                               Thomas R. Staab, II
                                                                               Chief Financial Officer and Treasurer

Dated: January 21, 2008

EXHIBIT INDEX

No.                 Description

99.1                Press Release dated January 18, 2008

EX-99.1

For Immediate Release

Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin
VP, Investor Relations and Corporate Communications
(919) 941-9777, Extension 219
Media Contact:
BMC Communications
Dan Budwick
(212) 477-9007, Extension 14

INSPIRE PROVIDES 2008 FINANCIAL GUIDANCE

DURHAM, NC - January 18, 2008 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH)
announced today revenue and expense guidance for the full year of 2008.

Inspire expects to record aggregate revenue in the range of $62-$76 million and expects
operating expenses to be in the range of $109-$129 million in 2008. Based on current operating
plans, the Company expects its cash and investments would provide liquidity through 2009. The
revenue range is based on projected sales from AzaSite (azithromycin ophthalmic solution) 1%
for bacterial conjunctivitis, Elestat (epinastine HCl ophthalmic solution) 0.05% for allergic
conjunctivitis and Restasis (cyclosporine ophthalmic emulsio n) 0.05% for dry eye. The
Company is withdrawing the guidance previously provided for AzaSite 2008 revenues.

Inspire will provide additional financial, operating and program details and assumptions when it
reports fourth quarter 2007 financial results on February 26, 2008 and hosts its quarterly earnings
conference call that day at 10:00 am ET.

About Inspire
Inspire is a biopharmaceutical company dedicated to discovering, developing and
commercializing prescription pharmaceutical products in disease areas with significant
commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the
promotion of AzaSite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis,
Elestat (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis
(cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic
areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cy stic
fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are registered trademarks owned by
Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more
information, visit www.inspirepharm.com.

Forward-Looking Statements
The forward-looking statements in this news release relating to management's expectations and
beliefs are based on preliminary information and management assumptions. Specifically, no
assurance can be made that the Company's aggregate 2008 revenue will reach the range
expected, that aggregate 2008 operating expenses will fall within the expected range, or that the
Company's current cash and investments will provide liquidity through 2009 or any other period
based on current operating plans. The Company may update its guidance in the future. Such
forward-looking statements are subject to a wide range of risks and uncertainties that could cause
results to differ in material respects, including those relating to pro duct development, revenue,
expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse
litigation developments, adverse developments in the U.S. Securities and Exchange Commission
(SEC) investigation, competitive products, results and timing of clinical trials, success of
marketing efforts, the need for additional research and testing, delays in manufacturing, funding,
and the timing and content of decisions made by regulatory authorities, including the U.S. Food
and Drug Administration. Further information regarding factors that could affect Inspire's results
is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements that may be made to reflect
events or circumstances after the date hereof.   
###

Page 2

4222 Emperor Boulevard, Suite 200 * Durham, North Carolina 27703
Telephone 919.941.9777    * Fax 919.941.9797

        

4222 Emperor Boulevard, Suite 200 * Durham, North Carolina 27703
Telephone 919.941.9777   * Fax 919.941.9797
-----END PRIVACY-ENHANCED MESSAGE-----